Founded in 1896, the Roche Group (headquartered in Basel, Switzerland) stands as one of the world’s oldest and largest biotech enterprises and a leader in in-vitro diagnostics. Our core philosophy — “Doing now what patients need next” — guides our operations. Roche Taiwan consistently fulfills its commitment to introducing global innovative achievements into the local market, and actively advocates for a premium environment conducive to long-term investment from international pharmaceutical companies.

Strategic Partnership to Bolster Taiwan’s Healthcare Resilience

Since establishing roots in Taiwan in 1967, Roche Taiwan has been a vital partner in the nation’s health journey. We maintain a diverse product portfolio, covering key therapeutic areas such as oncology, ophthalmology, immunology, and rare diseases, and remain dedicated to addressing major public health challenges.

We recognize that investing in R&D within these core areas is crucial for responding to significant and emerging medical needs. While Taiwan’s investment in innovative medicines shows room for growth compared to other advanced economies, Roche Taiwan sees this as a unique opportunity for the healthcare system to pivot — from primarily focusing on universal accessibility to becoming a global benchmark for the adoption of medical innovation.

Roche observes that Taiwan’s world-class healthcare infrastructure, professional medical teams, and established industry collaboration create a favorable environment for bringing international innovation to the local market. Roche Taiwan’s commitment extends beyond the mere supply of pharmaceuticals; it involves active collaboration to support the development of a healthcare ecosystem that is internationally aligned, sustainable, and resilient. Furthermore, we maintain close cooperation with patient organizations, ensuring that the patient voice is integral to the design of innovations and services, thereby providing more holistic, patient-centered care.

Strengthening Local Commitment: Strategic Investment in Data and R&D

Roche’s contribution to Taiwan is substantiated by its continuous, substantive investment in local R&D, which provides robust support for the long-term advancement of Taiwan’s healthcare system:

•       Robust Clinical R&D Engine: Clinical trials are a vital mechanism for advancing medical progress here. We annually invest over NT$100 million, with a pipeline exceeding 75 novel drug clinical trials underway as of October 2025, ensuring global cutting-edge treatments remain accessible locally.

•       Pioneering Precision Health: Roche Taiwan understands that prioritizing personalized precision medicine is essential for advancing cancer care. As an industry pioneer in driving breakthroughs, we were the first to provide approximately 2,000 comprehensive cancer genomic tests with corresponding treatment options. Roche Taiwan leveraged this invaluable real-world experience to provide important practical reference and data support for the Taiwan government’s decision-making process regarding the inclusion of next-generation sequencing testing in the National Health Insurance (NHI) reimbursement.

•       Data Collaboration and Evidence Contribution: Through close collaboration with medical partners, we launch local investigator-initiated research and real-world data cooperation projects. These findings gain international recognition and, importantly, utilize national databases to provide valuable evidence-based support for the optimization of healthcare policy in Taiwan.

Optimizing Resource Structure: Fostering Sustainable Accessibility to Innovation

Roche strongly believes that optimizing the allocation of pharmaceutical resources is critical to ensuring the Taiwanese healthcare system can consistently introduce the world’s most advanced, breakthrough therapies to the public.

While Taiwan’s NHI system provides broad and equitable coverage, we believe that increasing the share of innovative medicines within the overall pharmaceutical expenditure is essential to sustaining the vitality of medical innovation in Taiwan.

In countries such as Germany and Canada, patented medicines account for around 50% of total drug spending, while in Japan and Australia, single-source medicines make up about 60%. We hope that Taiwan can also establish measurable innovation indicators that can be tracked over time. This would not only ensure that patients continue to have timely access to globally aligned treatment options, but also signal to the international biopharmaceutical community that Taiwan is a market which values innovation and fosters long-term investment.

Roche Taiwan’s ultimate goal is to collaborate with the government and the healthcare system to continuously advance the integration of value and resources. Through this partnership, founded on shared objectives, we aspire to jointly build a more resilient and sustainably developed healthcare future for Taiwanese society, ensuring the “Healthy Taiwan” vision continues to benefit generations to come.